EBMT 2024 | Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant (alloSCT) setting in patients with relapsed myelofibrosis (MF). To date, two retrospective real-world studies have shown that these poor prognosis patients can achieve long-term remission with DLI. Dr Rampotas believes that if prospective studies can answer the questions surrounding the use of this therapeutic approach in the post-transplant setting, DLI has the potential to be a critical tool for improving the outcomes of these patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
